PT701449E - Processo de preparacao de uma forma de dosagem solida oral contendo diclofenac - Google Patents

Processo de preparacao de uma forma de dosagem solida oral contendo diclofenac

Info

Publication number
PT701449E
PT701449E PT94918361T PT94918361T PT701449E PT 701449 E PT701449 E PT 701449E PT 94918361 T PT94918361 T PT 94918361T PT 94918361 T PT94918361 T PT 94918361T PT 701449 E PT701449 E PT 701449E
Authority
PT
Portugal
Prior art keywords
pct
solid dosage
oral solid
preparing
containing diclofenac
Prior art date
Application number
PT94918361T
Other languages
English (en)
Inventor
Peter Heinrich Stahl
Claudio Gamboni
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT701449E publication Critical patent/PT701449E/pt

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT94918361T 1993-06-08 1994-05-24 Processo de preparacao de uma forma de dosagem solida oral contendo diclofenac PT701449E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH171193 1993-06-08

Publications (1)

Publication Number Publication Date
PT701449E true PT701449E (pt) 2003-12-31

Family

ID=4216820

Family Applications (1)

Application Number Title Priority Date Filing Date
PT94918361T PT701449E (pt) 1993-06-08 1994-05-24 Processo de preparacao de uma forma de dosagem solida oral contendo diclofenac

Country Status (14)

Country Link
US (1) US5702724A (pt)
EP (1) EP0701449B1 (pt)
JP (2) JPH08511009A (pt)
AT (1) ATE246515T1 (pt)
AU (1) AU6971294A (pt)
CA (1) CA2163111C (pt)
DE (1) DE69433012T2 (pt)
DK (1) DK0701449T3 (pt)
ES (1) ES2204918T3 (pt)
FI (1) FI116039B (pt)
NO (1) NO315844B1 (pt)
NZ (1) NZ267417A (pt)
PT (1) PT701449E (pt)
WO (1) WO1994028936A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0800384T3 (da) * 1994-12-14 2001-04-17 Enbalt Trading Ltd Pharmaceutiske tabletformuleringer til direkte kompression
HUP9600758A2 (en) * 1996-03-27 1998-03-02 Cyclolab Ciklodextrin Kutato F Diclofenac composition of diminished gastrointestinal irritation and enhanced biological resorption
US6720005B1 (en) * 2000-07-07 2004-04-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Coated, platform-generating tablet
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
PE20030323A1 (es) * 2001-08-31 2003-05-12 Novartis Ag Composicion farmaceutica
JP2005298338A (ja) * 2002-02-27 2005-10-27 Eisai Co Ltd 速崩壊性圧縮成形製剤
US20050123604A1 (en) * 2002-03-07 2005-06-09 Karnachi Anees A. Pharmaceutical compositions
US20040241234A1 (en) * 2003-06-02 2004-12-02 Alpharma, Inc. Controlled release press-coated formulations of water-soluble active agents
DE102004060914A1 (de) * 2004-12-17 2006-07-06 Bioghurt Biogarde Gmbh & Co. Kg Verwendung von Liponsäure-haltigen Cyclodextrin-Komplexen
EP1707217A1 (en) * 2004-12-17 2006-10-04 Wacker Chemie AG Process for preparing an alpha lipoic acid/cyclodextrin complex and product prepared
KR20160033796A (ko) * 2006-03-28 2016-03-28 자블린 파머슈티칼스 인코포레이티드 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
EP2003970A4 (en) * 2006-03-28 2012-07-11 Javelin Pharmaceuticals Inc FORMULATIONS OF NON-STEROID ANTI-INFLAMMATORY DRUGS WITH LOW DOSE AND BETA-CYCLODEXTRIN
US20110144207A1 (en) * 2008-08-14 2011-06-16 Shasun Chemicals And Drugs Limited Aryl alkyl carboxylic acid salts, process for preparation and dosage forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5959632A (ja) * 1982-09-28 1984-04-05 Teikoku Chem Ind Corp Ltd 徐放性組成物
JPS5984821A (ja) * 1982-11-04 1984-05-16 Teikoku Chem Ind Corp Ltd 徐溶化組成物
FR2660195B1 (fr) * 1990-03-28 1994-10-07 Crinex Sa Laboratoires Composition pharmaceutique a macher, antiinflammatoire et/ou analgesique.
IT1243342B (it) * 1990-07-13 1994-06-10 Farcon Ag Composizioni farmaceutiche orali liquide ad attivita' antiinfiammatoria
DE69013689T2 (de) * 1990-11-29 1995-03-02 Wei Ming Pharmaceutical Mfg Co Hilfsträger für direkte Verpressung.
US5231089A (en) * 1991-12-02 1993-07-27 University Of Florida Method of improving oral bioavailability of carbamazepine

Also Published As

Publication number Publication date
US5702724A (en) 1997-12-30
FI955837A0 (fi) 1995-12-04
JPH08511009A (ja) 1996-11-19
DE69433012D1 (de) 2003-09-11
DK0701449T3 (da) 2003-11-10
ES2204918T3 (es) 2004-05-01
EP0701449A1 (en) 1996-03-20
FI116039B (fi) 2005-09-15
NO954952L (no) 1995-12-06
NO315844B1 (no) 2003-11-03
NZ267417A (en) 1997-02-24
FI955837A (fi) 1995-12-04
ATE246515T1 (de) 2003-08-15
WO1994028936A1 (en) 1994-12-22
JP2005247874A (ja) 2005-09-15
CA2163111C (en) 2010-10-26
AU6971294A (en) 1995-01-03
NO954952D0 (no) 1995-12-06
DE69433012T2 (de) 2004-06-09
CA2163111A1 (en) 1994-12-22
EP0701449B1 (en) 2003-08-06

Similar Documents

Publication Publication Date Title
BR9407239A (pt) Azadioxacicloalquenos substituídos
PL314188A1 (en) Novel derivatives of benzoguanidine, method of obtaining them and their application in pharmaceutical compositions
BG102259A (en) Compostions with controlled paroxetine release
PT701449E (pt) Processo de preparacao de uma forma de dosagem solida oral contendo diclofenac
CA2047744A1 (en) Method for the synthesis of huperzine a and analogs thereof and compounds useful therein
UA19782A (uk) Спосіб одержаhhя біциклічhих складhих ефірів або їх фармацевтичhо прийhятhих солей
ATE147981T1 (de) Verabreichung von lamotrigin zur behandlung von neuro-aids
NZ320355A (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6- tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
HU9303000D0 (en) Aryl-morpholine-derivatives and pharmaceutical compositions containing it and process for production thereof
DE69104220T2 (de) Verfahren zur Herstellung von direktkomprimierten, Cephalosporansäure Derivate enthaltendenTabletten.
DK0866711T3 (da) Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö
NZ332545A (pt)
ATE216237T1 (de) Verwendung von ropivacaine zur herstellung eines analgetikums mit minimaler motorischer blockade
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
ATE173922T1 (de) 2-arylpropionsäure-zubereitungen und verfahren zu ihrer herstellung
AU4304596A (en) A process for the preparation of substituted 4-ethyl-piperidines and an intermediate for the preparation of same
UA37217C2 (uk) Аналоги 15-дезоксиспергуаліну, спосіб їх одержання, фармацевтична композиція та проміжні сполуки
DE69514512T2 (de) Verfahren zur herstellung von benzopyranderivaten
KR960700053A (ko) 방사선회복제로서 리루졸의 이용(application of riluzole as a radiorestorer)
MY133957A (en) "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor"
RU94013445A (ru) Новое соединение, лейстродуксин н, способ его получения и терапевтическая композиция
HU9401159D0 (en) New compound leustroducsin h, its preparation and pharmaceutical compositions containing them
MX9605668A (es) Sal de estilbazolio, su preparacion y uso.